Dr. Akmaev is the industry leader in AI and machine learning applications in life sciences and healthcare. He heads the Berg Analytics business division and is the chief architect of Bayesian Artificial Intelligence software, bAIcis®. Dr. Akmaev is an avid advocate for data driven research and promotes wider utility of advanced mathematical modeling techniques in pharmaceutical and clinical research. Prior to his role at BERG, Dr. Akmaev spent a decade at Genzyme R&D and the CLIA diagnostic laboratory, Genzyme Genetics. He led the development and commercialization of novel multi-omic panel diagnostics in oncology and prenatal medicine. Dr. Akmaev has published numerous peer-reviewed manuscripts in genomics, systems biology, biochemistry and human genetics. He is a frequent speaker at AI, analytics and precision medicine conferences. Dr. Akmaev holds a Ph.D. in Applied Mathematics from the University of Colorado at Boulder.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: AI has the potential to expedite the clinical drug discovery and development process by applying sophisticated algorithms to the analysis and mining of different data sources to predict molecule behavior and suitability as drug targets or therapeutic entities. This session will cover different approaches and AI platforms, and how they will impact the pharmaceutical industry and specifically, the drug discovery and development processes.